Compare AHMA & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | VTGN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 122.1M |
| IPO Year | 2025 | N/A |
| Metric | AHMA | VTGN |
|---|---|---|
| Price | $7.09 | $4.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 923.5K |
| Earning Date | 12-08-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $18,543,447.00 | $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | N/A | $478.23 |
| P/E Ratio | $213.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $1.90 |
| 52 Week High | $18.20 | $5.14 |
| Indicator | AHMA | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.67 |
| Support Level | N/A | $3.36 |
| Resistance Level | N/A | $4.97 |
| Average True Range (ATR) | 0.00 | 0.46 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 64.04 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.